Inter-individual variability in immune responses to AAV-mediated ocular gene delivery across species impedes reliable immunomonitoring profile
REN, D.; CHAUVEAU, G.; VENDOMELE, J.; CABON, E.; PINEIRO, A.; VIGNAL-CLERMONT, C.; SALIBA, H.; RONZITTI, G.; GALY, A.; DALKARA, D.; PULMAN, J.; AIL, D.; FISSON, S.
Show abstract
Adeno-associated viruses (AAVs) have been used in gene therapy, especially for inherited retinal diseases. Despite their effectiveness in gene transduction, immune responses to the AAV capsid and transgene products have been reported, which can compromise both the efficacy and safety of AAV-mediated therapies. The eye is regarded as an immune-privileged organ where immune activity is constitutively suppressed. Here, we highlight that immunomonitoring in an ocular gene transfer reveals variable immune responses, whatever the species (human clinical trial, non-human primates, mice), the site of injection, the cassette, and the dose. We further explored factors contributing to this variability, investigating the correlation among immune parameters in a controlled experimental setting. In a syngeneic murine model after an intraocular injection of AAV, our results highlight an inter-individual variability of immune parameters, emphasizing the importance of considering inherent variability among individuals while designing personalized therapies.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.